Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Juliana Janoski"'
Autor:
Krämer, Alwin *, Bochtler, Tilmann, Pauli, Chantal, Shiu, Kai-Keen, Cook, Natalie, de Menezes, Juliana Janoski, Pazo-Cid, Roberto A, Losa, Ferran, Robbrecht, Debbie GJ, Tomášek, Jiří, Arslan, Cagatay, Özgüroğlu, Mustafa, Stahl, Michael, Bigot, Frédéric, Kim, Sun Young, Naito, Yoichi, Italiano, Antoine, Chalabi, Nasséra, Durán-Pacheco, Gonzalo, Michaud, Chantal, Scarato, Jeremy, Thomas, Marlene, Ross, Jeffrey S, Moch, Holger, Mileshkin, Linda
Publikováno v:
In The Lancet 10-16 August 2024 404(10452):527-539
Autor:
Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi
Publikováno v:
NEJM Evidence. 2
Autor:
Hussein A, Tawbi, Dirk, Schadendorf, Evan J, Lipson, Paolo A, Ascierto, Luis, Matamala, Erika, Castillo Gutiérrez, Piotr, Rutkowski, Helen J, Gogas, Christopher D, Lao, Juliana Janoski, De Menezes, Stéphane, Dalle, Ana, Arance, Jean-Jacques, Grob, Shivani, Srivastava, Mena, Abaskharoun, Melissa, Hamilton, Sarah, Keidel, Katy L, Simonsen, Anne Marie, Sobiesk, Bin, Li, F Stephen, Hodi, Georgina V, Long, Sajeve, Thomas
Publikováno v:
The New England journal of medicine. 386(1)
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking a
BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::decb87d233c44708515fa6a62bfd0109
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3034001
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3034001
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
X. Zhang, Michael Schenker, Shunyuan Lu, Arnaud Scherpereel, Maurice Pérol, A. Lingua, Manuel Cobo, S. Marimuthu, Tudor-Eliade Ciuleanu, Arteid Memaj, Eduardo Richardet, O. Juan-Vidal, F. Reyes, David P. Carbone, B. Zurawski, A. Alexandru, Phuong Tran, Hiroshi Sakai, Jaafar Bennouna, Martin Reck, Enriqueta Felip, Thomas John, Juliana Janoski de Menezes, Pierre-Jean Souquet, C. Martin, Luis Paz-Ares, P. De Marchi
Publikováno v:
ESMO Open
ESMO Open, 2021, 6 (5), pp.100273. ⟨10.1016/j.esmoop.2021.100273⟩
Scientia
Esmo Open
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ESMO Open, 2021, 6 (5), pp.100273. ⟨10.1016/j.esmoop.2021.100273⟩
Scientia
Esmo Open
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Background To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9589559f779d6c7e2f62cb2eac8678f
https://www.hal.inserm.fr/inserm-03540859/document
https://www.hal.inserm.fr/inserm-03540859/document
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo-Dols, Jaafar Bennouna, Ying Cheng, Hideaki Mizutani, Alejo Lingua, Felipe Reyes, Niels Reinmuth, Juliana Janoski De Menezes, Jacek Jassem, Svetlana Protsenko, Kynan Feeney, Emmanuel De La Mora Jimenez, Shun Lu, Tom John, David Paul Carbone, Xiaoqing Zhang, Nan Hu, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 40:LBA9026-LBA9026
LBA9026 Background: In CheckMate 9LA (NCT03215706), 1L NIVO + IPI combined with 2 cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic NSCLC. Here, we report updated efficacy and safety with a 3-year minimum fol
Autor:
Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Sarah Keidel, Karin Jonczak, Anne Marie Sobiesk, Sonia Dolfi, Georgina V. Long
Publikováno v:
Journal of Clinical Oncology. 40:9505-9505
9505 Background: In the phase 2/3 RELATIVITY-047 trial, NIVO + RELA as a fixed-dose combination (FDC) significantly improved the primary endpoint of progression-free survival (PFS) versus NIVO in patients (pts) with previously untreated metastatic or
Autor:
Andrew J. Armstrong, Noel W. Clarke, Antoine Thiery-Vuillemin, Mototsugu Oya, Giuseppe Procopio, Juliana Janoski De Menezes, Gustavo Colagiovanni Girotto, Pooja Ghatalia, Franco Nole, Omar Din, Philipp Spiegelhalder, Ivan Mincik, Robbert J. van Alphen, Nicolaas Lumen, Christian Hosius, Diansong Zhou, Laura Barker, Melanie Elizabeth Dujka, Fred Saad
Publikováno v:
Journal of Clinical Oncology. 40:5050-5050
5050 Background: PROpel (NCT03732820) is a double-blind, Phase III trial of abiraterone + olaparib vs abiraterone + placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Here we report results from
Autor:
Phuong Tran, Aurella Alexandru, S. Marimuthu, Tudor-Eliade Ciuleanu, Hiroshi Sakai, Manuel Cobo, Luis Paz-Ares, Michael Schenker, Jaafar Bennouna, Arnaud Scherpereel, Arteid Memaj, Enriqueta Felip, O. Juan-Vidal, David P. Carbone, B. Zurawski, Thomas John, Eduardo Richardet, Juliana Janoski de Menezes, Shun Lu, Martin Reck
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.9000-9000. ⟨10.1200/JCO.2021.39.15_suppl.9000⟩
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.9000-9000. ⟨10.1200/JCO.2021.39.15_suppl.9000⟩
9000 Background: In the randomized phase 3 CheckMate 9LA trial (NCT03215706), first-line NIVO + IPI combined with 2 cycles of chemo significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) vs ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b2800a2aa277d299a7b3e6fbe4f791
https://www.hal.inserm.fr/inserm-03540833
https://www.hal.inserm.fr/inserm-03540833